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Summary. Proteolysis of vascular basement membranes 
and surrounding extracellular matrix is a critica1 early 
step in neovascularization. It requires alteration of the 
balance between matrix metalloproteinases (MMPs) and 
proteins that bind to and inactivate MMPs, tissue 
inhibitors of metalloproteinases (TIMPs). TIMP-1 has 
been demonstrated to inhibit neovascularization in chick 
chorioallantoic membranes. However, TIMP-1 has also 
been shown to either promote or inhibit cell proliferation 
and migration in different settings. To determine whether 
genetic alteration of the MMPDIMP-1 ratio would alter 
retinal neovascularization, we crossed mice that express 
vascular endothelial growth factor (VEGF) in 
photoreceptors with TIMP-1-deficient mice or mice that 
overexpress TIMP-1. Compared to VEGF transgene- 
positive/TIMP-1-sufficient mice, VEGF transgene- 
positive1TIMP-1-deficient mice showed smaller  
neovascular lesions. There was also no difference 
between the two groups of mice in the appearance of the 
neovascularization by light or electron microscopy. 
Compound VEGFITIMP-1 transgenic mice had 
increased expression of both VEGF and TIMP-1 in the 
retina, and had more neovascularization than mice that 
had increased expression of VEGF alone. These gain- 
and loss-of-function data suggest that alteration of the 
TIMP-1MMP ratio modulates retinal neovascularization 
in a complex manner and not simply by altering the 
proteolytic activity and thereby invasiveness of 
endothelial cells. 
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lntroduction 
Neovascularization (NV) occurs by the formation of 
endothelial cell sprouts from pre-existent blood vessels. 
This process involves degradation of vascular basement 
membranes and surrounding tissue (Ausprunk and 
Follunan, 1977; Kalebic et al., 1983). Angiogenic factors 
cause endothelial cells to increase their expression of 
one or more matrix metalloproteinases (MMPs), a family 
of homologous enzymes that digest a wide variety of 
extracellular matrix (ECM) components including 
collagens, fibronectin, laminin, and various proteo- 
glycans (Moscatelli et al., 1980,1985; Gross et al., 1983; 
Mignatti et al., 1989). Each of the MMPs is secreted in 
zymogen form and requires proteolytic cleavage to 
become active (Woessner, 1991). Their activity is also 
modulated by a family of inhibitors, the tissue inhibitors 
of metalloproteinases (TIMPs). Four members of this 
family have been cloned, TIMPs-1, -2, -3, and -4 
(Docherty et al., 1985; Carmichael et al., 1986; Stetler- 
Stevenson et al., 1989; Pavloff et al., 1992; Greene et al., 
1996; Leco et al., 1997). a2-Macroglobulin, which has 
broad inhibitory activity, also inhibits MMPs (Kan et al., 
1985). 
There is mounting evidence suggesting that invasive 
cell behavior, including metastasis and NV, is controlled 
in part by the local balance between MMPs and their 
inhibitors. Tumor necrosis factor-a, an angiogenesis 
factor, increases expression of collagenase and decreases 
expression of TIMP-1 in human dermal microvascular 
endothelial cells (Cornelius et al., 1995). Cartilage, an 
avascular tissue that resists vascular invasion, has high 
levels of TIMPs which inhibit NV in vivo (Moses et al., 
1990; Johnson et al., 1994). TIMP-1 is also present in 
substantial levels in the vitreous, an avascular tissue in 
the eye (Bunning et al., 1984). Therefore, TiMP-1 may 
help to protect tissues from invasion by endothelial cells 
and the leve1 of protection may be altered by changes in 
TIMP-1 expression. This possibility is supported by 
recent studies demonstrating that expression of a 
transfected TiMP-1 gene in melanoma cells lowers their 
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tumorigenic and metastatic potentials (Khokha, 1994) 
and targeted disruption of the Timp-1 gene causes 
enhanced invasion of normal differentiated cells and 
increased metastatic potential of transformed cells 
(Alexander and Werb, 1992). But, it is not the case that 
an increase in the TIMPIMMP ratio always increases 
invasive cell behavior such as angiogenesis, or that a 
decrease in the ratio always decreases it. An excess of 
proteolysis or inhibitors may have opposite or similar 
effects, depending upon whether critical amounts of 
ECM components required for attachment, survival, and 
proliferation are present (Yoshiji et al., 1998; Zucker et 
al., 1998). Some tumor cells grow and metastasize less 
well in the absence of TIMP-1 (Soloway et al., 1996), 
suggesting that TIMP-1 may act as a growth and survival 
factor. 
The vascular supply of the retina is  highly 
specialized due to requirements related to visual 
function. Retinal blood vessels supply the inner retina 
via a superficial capillary bed in the nerve fiber layer and 
deep capillary beds in the inner nuclear and outer 
plexiform layers. Normally there are no blood vessels in 
the outer retina; photoreceptors are maintained by 
diffusion from choroidal vessels. We have previously 
demonstrated that expression of VEGF in photoreceptors 
of transgenic mice results in vascular invasion of the 
outer retina (Okamoto et al., 1997; Tobe et al., 1998). In 
these mice, endothelial cells migrate from the deep 
capillary bed of the retina, through the outer nuclear 
layer into the subretinal space where they form new 
blood vessels that gradually enlarge. No NV originating 
from the choroidal vessels has been identified. It is 
possible that like other avascular tissues, TIMP-1 may 
regulate the extent of NV originating from retinal vessels 
and vascular invasion from the choroid. In this study, we 
used mice with targeted disniption of the Timp-1 gene 
and transgenic mice that overexpress Timp-1 to 
investigate whether Timp-1 contributes to a critical 
balance that limits the progression and extent of NV in 
the outer retina and subretinal space. 
Materials and methods 
Mice with targeted deletion of Timp- 1 
Timp-1 null mice were generated by homologous 
recombination and identified by Southern blotting as 
previously described (Soloway et al., 1996). Since 
Timp-1 is located on the X chromosome, al1 male 
offspring of female Timp-1-null mice and wild type 
males are null. 
Model of intraretinal and subretinal NV 
The production and screening of transgenic mice 
with overexpression of VEGF in photoreceptors (rho- 
VEGF transgenics) has been previously described 
(Okamoto et al., 1997). Mice from the V-6 line 
heterozygous for the rhodopsinlVEGF transgene develop 
NV that originates from the deep capillary bed of the 
retina and grows into the subretinal space where it 
gradually spreads and enlarges. Heterozygous transgenic 
males were mated with female Timp-1 -1- or Thp-l+I+ 
mice of the same genetic background. At six weeks of 
age, male rho-VEGFITirnp-1 -/O and rho-VEGFITimp- 
1+ lO  (controls) were perfused with fluorescein-labeled 
dextran and their eyes were used to make retinal flat- 
mounts or the mice were sacrificed without perfusion 
and their eyes were used for light and electron 
microscop y. 
Transgenic mice that overexpress Timp- 1 
Heterozygous transgenic mice overexpressing the 
human TIMP-1 gene under the control of the ubiquitous 
B-actin promoter (B-actin-TIMP-1 mice) (Alexander et 
al., 1996) were mated with rho-VEGF transgenic mice. 
At 3 weeks of age, the offspring were perfused with 
fluorescein-labeled dextran and retinal whole mounts 
were prepared. The mice were genotyped by PCR and 
Southern blotting of tail DNA. 
Northern Blot Analysis 
RNA blot hybridization analysis was done as 
previously described (Campochiaro et al., 1994) using 
10 pg of total retinal RNA. The cDNA probe was the 
598 bp BamHI fragment of hVEGF labeled with 3 2 ~  by 
hexanucleotide random priming (Okamoto et al., 1997). 
Hybridization temperature was 42 "C. The membrane 
was washed twice for 30 minutes at 60 OC in 1 x SSC, 
0.2% SDS, followed by two washes of 30 minutes each 
at 65 "C in 0.2 x SSC, 0.2% SDS. Washed blots were 
exposed to XRP film (Kodak, Rochester, NY) and 
multiple exposure times were used to obtain exposures 
within the linear range for autoradiographic signals. 
Blots were stripped and rehybridized with a 0.8 kb 
cDNA fragment coding for most of exon 2 and al1 of 
exon 3 of the human FGF2 gene (Abraham et al., 1986). 
After exposure, the blots were stripped and hybridized 
with a probe for 18s  ribosomal RNA to control for 
potential differences in RNA loading. 
Retinal flat mounts 
Retinal flat mounts were prepared by modification 
of a previously described technique (Smith et al., 1994; 
Tobe et al., 1998). Mice were anesthetized, the 
descending aorta was clamped, the right atrium was cut, 
and they were perfused through the left ventricle with 1 
m1 of phosphate-buffered saline containing 50 mg/ml of 
fluorescein-labeled dextran (2x10~ average mw, Sigrna, 
St. Louis, MO). The eyes were removed and fixed for 1 
hour in 10% buffered formalin phosphate. The cornea 
and lens were removed and then the entire retina was 
carefully dissected from the eyecup, radially cut from the 
edge of the retina to the equator in al1 4 quadrants, and 
flat-mounted in Aquamount with photoreceptors facing 
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upward. Flat mounts were examined by fluorescence 
microscopy, photographed with T-64 film (Kodak, 
Rochester, NY), and sl ides were scanned with a 
QuickScan 35 scanner (Minolta, Osaka, Japan). Image 
files were imported into Adobe Photoshop 4.0, labeled, 
and printed with a Fujix pictography 3000 printer (Fuji 
Photo Film Co., Tokyo, Japan). 
Quantitation of retinal NV 
Retina1 flat mounts were examined by fluorescence 
microscopy at 400x magnification, which provides a 
narrow depth of field so that when focusing on NV on 
the outer edge of the retina the remainder of the retinal 
vessels are out-of-focus allowing easy delineation of the 
NV. The outer edge of the retina, which corresponds to 
the subretinal space in vivo, is easily identified and 
therefore there is standardization of foca1 plane from 
slide to slide. Images were digitized using a 3 CCD color 
video camera (IK-Tü40A, Toshiba, Tokyo, Japan) and a 
frame grabber. Image-Pro Plus software (Media 
Cybernetics, Silver Spring, MD) was used to delineate 
each of the lesions and calculate the number in each 
retina, the area of each lesion, and the total area of 
neovascularization per retina. Measurements were 
repeated three times for each retina and the mean was 
used for one experimental value; there was lit t le 
variability among triplicate measurements. 
Light and electron microscopy 
Eyes were fixed in 4% glutaraldehyde in 0.1M 
cacodylate buffer (pH 7.4) for 24 hours at 4 'C. The 
anterior segments were removed and the posterior 
eyecups were divided into 4 parts. Segments of tissue 
were postfixed with 1% osmium tetroxide/cacodylate 
buffer (pH 7.4), dehydrated through a series of graded 
alcohols, and embedded in PolyIBed 8 1 2  resin 
(Polysciences, Warrington, PA). One micron serial 
sections were cut, stained with Toluidine Blue, and 
examined with an Axioscope microscope (Zeiss, 
Thomwood, NY). Sections were photographed, scanned, 
labeled, and printed as described above. For electron 
microscopy, ultrathin sections were cut, counterstained 
with 2.0% uranyl acetate and 0.3% lead citrate, and 
Table 1. Quantitation of neovascularization in the photoreceptor layer in 
VEGF+lTimp-1-wild iype and VEGF+lTimpl-null mice 6 weeks after 
birth. 
Timp-1 N LESIONSI AREAJLESIONS NV AREAIRETINA 
RETINA (mm2xl@) (mm2xl0-3) 
Wild type 20 25.1 511.96 6.0520.52 147.4721 6.29 
Null 14 28.0712.94+ 4.2010.23* 1 16.1 921 1.41 + 
*: p=0.0034 for dierence from wild iype by a t-test for populations with 
unequal variances; +: not significant for difference from wild type by a t- 
test for populations with equal variances. 
examined with a transmission electron microscope 
(JEOL 100CX). 
Results 
TIMP- 1 -deficient mice have normal-appearing retinas 
Evaluation of sections from the eyes of TIMP-1- 
deficient mice through 6 weeks of age by light 
microscopy showed normal-appearing retinas with no 
identifiable retinal phenotype (not shown). 
Rho-VEGFflIMP-1-deficient mice have no difference in 
total amount of neovascularization, but have smaller 
neovascular lesions than those in rho-VEGFfllMP-1- 
suficient mice 
As  noted previously in mice with a C57BL16J 
genetic background (Okamoto et al., 1997; Tobe et al., 
1998) Fl(129Sv x C57BW6J) mice, that were TIMP-1- 
sufficient and inherited a rhodopsinlVEGF transgene, 
developed NV originating from the deep capiilary bed of 
the retina that extended through the photoreceptors into 
the subretinal space (Fig. lA,B). TIMP-1-deficient mice 
that inherited a rhodopsinlVEGF transgene, also showed 
NV extending from retinal vessels into the subretinal 
space (Fig. lC,D). There were no identifiable qualitative 
morphological differences by light microscopy in the 
NV in TIMP-1-deficient compared to TIMP-1-sufficient 
mice and neither showed evidence of NV originating 
from the choroid. 
The amount of NV in rho-VEGFD'IMP-1-deficient 
and rho-VEGFDIMP-1-sufficient mice was measured on 
retinal flat mounts after perfusion with fluorescein- 
labeled dextran, a technique that has previously been 
demonstrated to provide good quantitation of NV (Tobe 
et al., 1998). Figure 2A shows the entire retina from a 
rho-VEGFITIMP-1-sufficient mouse. At this low 
magnification it is difficult to resolve the NV, but the 
pigmented cells (arrows) associated with NV can be 
seen. At higher magnification, the new vessels that are 
surrounded by pigmented cells are easily seen (Fig. 2B, 
arrows). The  amount of pigment seen at low 
magnification (Fig. 2C, arrows), and the new vessels 
seen at higher magnification (Fig. 2D, arrows) are 
comparable in rho-VEGFITIMP-1-deficient mice. 
Quantitation of the NV by image analysis showed that 
rho-VEGFITIMP-1-deficient mice had smaller 
neovascular lesions than rho-VEGFjTIMP-1-sufficient 
mice and there was no significant difference in the 
number of NV lesions or the total area of NV per retina 
(Table 1). 
There is no identifiable difference in the ultrastructure of 
NV in rho-VEGFflIMP- 1 -deficient mice compared to rho- 
VEGFRIMP- 1 -sutficient mice 
Electron microscopy of the subretinal NV in rho- 
VEGFfI'IMP-1-sufficient mice showed that many of the 
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new vessels were completely surrounded by retinal 
pigmented epithelial (RPE) cells in the plane of the 
section, and as previously noted (Tobe et al., 1998), most 
of these vessels had fairly thick endothelial cells with no 
fenestrations (Fig. 3A). A few of the vessels surrounded 
by RPE cells in the plane of the section, and al1 vessels 
not surrounded by RPE cells, had thin endothelial cells 
with fenestrations (Fig. 3B). New vessels with each type 
of morphology were also seen in rho-VEGFITIMP-1- 
deficient mice (Fig. 4). 
Rho-VEGF/B-actin-TIMP- 1 mice have more NV than rho- 
VEGF mice with the same genetic background 
While the investigations comparing the amount of 
NV in 6 week old rho-VEGFfí'IMP-1-deficient and rho- 
VEGFITIMP-1-sufficient mice (Table 1 )  were in 
progress, we completed time course experiments and 
found that 3 weeks of age provides an even better time 
point for assessment of modulation of NV in rho-VEGF 
mice (Tobe et al., 1998). Therefore, we investigated the 
effect of increased expression of TIMP-1 on VEGF- 
induced NV at the 3 week time point. Retina1 whole 
mounts of 3 week old rho-VEGFIB-actin-TIMP-1 mice 
showed extensive intraretinal and subretinal NV (Fig. 
5A,B) that was greater than that seen in littermates that 
inherited the VEGF transgene, but not the TIMP-1 
transgene (Fig. 5C,D). Quantitation of the NV by image 
analysis demonstrated significantly more neovascular 
lesions per retina and greater total area of NV per retina 
in rho-VEGFIB-actin-TIMP-1 mice (Fig. 6). Mice that 
carried only the TIMP-1 transgene did not have any NV. 
Northern blots showed only small,  inconsistent 
differences in VEGF or FGF2 mRNA levels in the 
retinas of rho-VEGF mice that over-expressed TIMP-1 
compared to the levels in mice with normal TIMP-1 
levels (Fig. 7). These small differences in mRNA levels 
do not provide an explanation for the difference in NV. 
Discussion 
VEGF is a stimulator of NV in the retina. Transgenic 
Fig. 1. lntraretinai and subretinal neovascularization in Timp-1-wild type (A and B) and Timp-1-deficient (C and D) mice that overexpress VEGF in 
photoreceptors. A. 6 week-old VEGF+lTimpl-wild type mouse has a large blood vessel extending from !he inner nuclear layer, through the outer 
nuclear layer (uppennost arrow) to a plexus of blood vessels in the subretinal space (lower arrows). The blood vessels are partially surrounded by RPE 
cells (arrowheads). B. Another 6 week-old VEGF+lTimpl-wild type mouse shows similar findings !o those seen in (A). C. A 6 week-old VEGF+ITímpl- 
deficient mouse shows a network of blood vessels (arrows) in the subretinal space surrounded by RPE cells (arrowheads) with a feeder vessel from the 
inner retina seen in the outer nuclear layer (upper arrows). Another 6 week-old VEGF+lTimp-1-deficient mouse shows findings similar to those seen in 
A-C. x 400 
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mice with ectopic expression of VEGF in photoreceptors 
develop sprouts of NV from retinal vessels in the deep 
capillary bed of the retina extending through the outer 
nuclear layer into the subretinal space (Okamoto et al., 
1997; Tobe et al., 1998). The NV becomes surrounded 
by RPE cells and gradually spreads and coalesces. 
Although choroidal vessels are located closer to 
photoreceptors, where VEGF is produced, no choroidal 
NV occurs. These observations raise the question, does 
something in the outer retina andlor something produced 
by the RPE, protect against and limit vascular invasion 
of the outer retina? TIMP-1, along with other MMP 
inhibitors, has been postulated to play such a role 
(Bunning et al., 1984) and it is produced by cultured and 
in situ RPE cells (Alexander et al., 1990; Padgett et al., 
1997). To investigate the hypothesis that TIMP-1 acts as 
an inhibitor of NV in the outer retina, we crossed rho- 
VEGF transgenic mice with TIMP-1-deñcient or TIMP- 
1 overexpressing mice. 
VEGF transgene-positive mice deficient in TIMP-1 
showed significantly smaller neovascular lesions 
compared to VEGF transgene-positive, TIMP-1- 
sufficient mice with the same genetic background. This 
difference suggests that TIMP-1 may not limit NV in the 
outer retina, and raises the question of whether loss of 
TIMP-1 antagonizes the development of NV in the 
retina. If this is the case, it might be expected that 
increased expression of TIMP-1 would promote the 
development of NV. Evaluation of rho-VEGFIP-actin- 
TIMP-1 mice suggests that this is the case, because they 
showed significantly greater total area of NV per retina 
than littermates that inherited the VEGF transgene, but 
not the TIMP-1 transgene. Taken together with the data 
in TIMP-1-deficient mice, these data suggest that in the 
presence of excess VEGF, TIMP-1 functions as a 
positive regulator of NV in the retina. 
While proteolytic activity is needed for breakdown 
of the basement membrane to allow endothelial cell 
Fig. 2. Retinal whole-mounts in mice perfused with fluorescein-labeled dextran. A. A low magnification (25x) view of the entire retina in a VEGF 
transgene-positive mouse with a wild type Timp-1 allele. It is difficult to resolve the neovascularization, but the pigmented cells (arrows) associated with 
neovascularization give a rough idea of the total amount of neovascularization. B. Higher magnification (1000~) of the retina seen in (A), the 
neovascularization (some. but not al1 of which is marked by asterisks) is easily distinguished. Note the adjacent retinal pigmented epithelial cells 
(arrows). C. At low magnification (25x) of a retina from a VEGF transgene-positivelTimp-1-deficient mouse, there are pigmented cells (arrows) roughly 
comparable to those seen in (A). D. Higher magnification (1000~) of the retina seen in (C), shows the neovascularization (asterisks) and adjacent 
retinal pigmented epithelial cells (arrows). 
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sprouting and growth of new vessels through avascular 
tissue, alteration of the MMPITIMP-1 ratio could affect 
the process of NV in other ways. The ECM provides 
signals to endothelial cells that can either potentiate the 
effects of angiogenic stimuli or promote differentiation 
and decrease responsiveness to angiogenic stimuli 
(Schwartz and Ingber, 1994; Ingber et al., 1995; Dike 
and Ingber, 1996). It is likely that a decrease in the 
MMP/TIMP-1 ratio results in decreased ECM turnover 
and alteration of its content, which could perturb the 
differentiation-promoting effects of the ECM and make 
endothelial cells more prone to form sprouts in the 
presence of VEGF. Also, TIMP-1 can regulate VEGF 
production and stability (Yoshiji et al., 1998). Another 
possibility is that NV is kept in check by an endogenous 
inhibitor(s), such as transforming growth factor4 (TGF- 
B, that requires activation by MMPs. Pericytes that 
contact endothelial cells in cocultures inhibit endothelial 
cell growth by secretion of TGF-B that is activated by 
proteinases at the cell surface (Antonelli-Orlidge et al., 
1989;  Sa to  e t  al., 1990). Rats with experimental 
autoimmune uveoretinitis (EAU) express high levels of 
VEGF and TGF-B in the retina and do not develop 
retinal NV, while rats with ischemic retinopathy express 
high levels of VEGF and low levels of TGF-B and 
develop retinal NV (Vinores et al., 1998). Therefore, 
TGF-B may be an endogenous negative regulator of 
retinal angiogenesis and since MMPs participate in its 
activation, a decrease in the MMPiTIMP-1 ratio might 
result in a decrease in active TGF-B and thereby greater 
iig. 3. Hectron micmcopy oi subretinal neovascularization in VEGF transgenic mice with a wild type Tlmpl allele. A A new vessel (arrow) in the 
subretinal space oi a VEGF transgane-posttive mwse with a wild trpe Timpl allele has thkk endothelial cells with no fenestrations. Beneath the 
vessel there is an intact layer oi retinal pigmented epithelial ceils (RPE) adjacent to BNCWS membrane (Br) and ihe choriocapillaris (CC). There are 
also RPE ceils above the vessel and aithough they were sxcluded from this micrograph, there were RPE cells completely surrounding the vessel in the 
p h  oi the secüon. B. Another VEGF transgene-positive rnouse with a wild type i imp l  alleie has a new Mood vessel in the subretinal space that is 
pattially surrounded by RPE cells and has thin endothelial 41s with fenestrations (inset, a m ) .  
Flg. 4. Electron mlcroscopy of subretinal 
neovascularization in VEGF transgenic mice deñcient 
in Timp-l. A. New blood vessels in the subretinal 
space of a VEGF transgene-positi/iimpl-deficlent 
mouse are surrounded by RPE cells and have 
relatively thick endothelial cells with no fenestrations. 
The RPE cells above the vessels have few pigment 
granules, while those adjacent to Bmch's membrane 
(Br) and the choriocapillaris (CC) have numerous 
pigment granules. B. Another VEGF transgene- 
positiive/Timp 1 -deRcient mouse shows a new vessel 
in the subretinal space that is wmpletely surrounded 
by RPE cells, but has thin endothellal cells with many 
fenestrations. C. The region within the box in (E) is 
shown at higher magnkation to show fenestrations 
(arrows). 
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VEGF-induced retinal NV. Similarly, angiostatin 
(O'Reilly et al., 1994) and endostatin (O'Reilly et al., 
1997) are angiogenesis inhibitors that are cleavage 
products of large proteins generated by MMPs and a 
decrease in the MMPtTIMP-1 ratio rnay promote retinal 
NV in part by decreasing angiostatin andlor endostatin 
levels. 
Our results should not be interpreted to suggest that 
inhibition of proteolysis does not provide a protective 
influence against the development of NV in the outer 
retina and subretinal space, because protection rnay be 
mediated by inhibitors other than TIMP-1. In some 
systems, TIMP-2 inhibits endothelial cell processes 
associated with angiogenesis to a greater extent than 
TIMP-1 (Murphy et al., 1993), and if this is the case in 
the retina, TIMP-2, but not TIMP-1, rnay help to prevent 
retinal neovascularization. Individuals in two pedigrees 
with Sorsby's fundus dystrophy were found to carry 
mutations in the TIMP-3 gene (Weber et al., 1994). 
Sorsby's fundus dystrophy is an autosomal dominantly 
inherited disease in which patients have a high incidence 
of early-onset choroidal NV (Sorsby et al., 1949; Hoskin 
et al., 1981; Capon et al., 1988). Within the eye, TIMP-3 
is differentially expressed in the RPE @ella et al., 1996; 
Ruiz et al., 1996) and therefore perturbation of TIMP-3 
activity in RPE cells rnay predispose to choroidal NV. 
Although TIMP-1 and TIMP-3 have a similar 
antiproteolytic spectrum of activity, TIMP-3 has greater 
affinity for ECM (Pavloff et al., 1992) and association 
with the ECM rnay be  critical for  limitation of 
proteolysis in the subretinal space. 
The mechanism by which increased expression of 
TIMP-1 increases VEGF-induced retinal NV is unclear. 
It rnay be due to an activity o£ TIMP-1 other than its 
inhibition of proteolysis. For instante, TIMP-1 has been 
demonstrated to stimulate the proliferation of severa1 cell 
types in vitro (Bertaux et al., 1991; Hayakawa et al., 
1992). This rnay occur by TIMP-1-mediated protection 
of matrix-bound growth factors  or  other ECM 
components critical for cell survival. If TIMP-1 has the 
same effect on endothelial cells in vivo, this could 
enhance VEGF-induced retinal NV. On the other hand, if 
the stimulatory effect of TIMP-1 on retinal NV is related 
to its inhibition of metalloproteinase activity, then it is 
unlikely that synthetic proteinase inhibitors will provide 
therapeutic benefit in patients with retinal NV. 
Flg. 5. Mice that overexpress TIMP-1 have increased VEGF-induced retinal neovascularization at 3 weeks of age compared to liermate controls 
A. Double transgenic mice that overexpress TIMP-1 and VEGF in the retina show many small hyperfluorescent spots corresponding to areas of 
neovascularization. x 25. B. At higher magnification, focusing on the outer edge of the retina, numerous neovascular lesions partially surrounded by 
retinal pigmented epithelial cells are seen. The dark area marked is the region where the optic nerve formerly entered the retina. x 100. C. A littermate 
that overexpresses VEGF, but not TIMP-1, shows fewer hyperfluorescent spots corresponding to neovascularization than seen in (A). x 25. D. At higher 
magnification, focusing on the outer edge of the same retina shown in (C), a few neovascular lesions are seen, but many fewer than in (B). x 100 
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Neovascularization is a complex process that is 
likely to result from disturbance of a critica1 balance 
between stimulatory and inhibitory factors, and the Timpl 
Flg. 6. Mice that overexpress TIMP-1 and VEGF in the retina have more 
neovascular lesions and a greater total area of neovascularization than 
mice that overexpress VEGF, but not TIMP-1. Retinal whole mounts of 
fluorescein-labeled dextran perfused 3 week old mice that overexpress 
TIMP-1 and VEGF (TIMP-l+IVEGF+; n=19) and littermates that 
overexpress VEGF, but not TIMP-1 (VEGF+; n= l l )  were examined by 
fluorescence microscopy and the number of neovascular lesions per 
retina, the area per lesion, and the total area of neovascularization per 
retina were quantitated by image analysis. The bars represent the mean 
+ SEM. *: p=0.0053; *: p=0.0039 for dierence from VEGF+ liermates 
by a t-test for populations with unequal variances +p=0.91 for dierence 
from VEGF+ littermates by a t-test for populations with equal variances. 
Flg. 7. There are no differences in VEGF or FGF2 mRNA levels to 
explain the difference in neovascularization in rho/VEGF mice that 
overexpress TIMP-1 cornpared to those that have normal TIMP-1 levels. 
Northern blots demonstrate only small dmerences in VEGF and FGFP 
mRNA in the retinas of 3 week old rho-VEGF mice that express 
increased levels of TIMP-1 compared to those with normal TIMP-1 
expression. Blots were also hvbridized with a DrObe for 18s which 
shows no diíference in loading. . 
factors  involved may vary from tissue to tissue. 
Identification of the factors involved in any particular 
tissue is likely to be a dificult task, but is worthwhile 
because it can help direct development of pharmacologic 
and gene therapies. Our strategy for the retina, is to use 
leads obtained from in vitro studies or models in other 
tissues and methodically test them using genetically 
engineered mice. Our studies thus far suggest that VEGF 
is an irnportant stimulatory factor for NV in the retina, 
and while TIMP-1 plays an important role in limiting 
cellular invasion in severa1 tissues, and NV in some 
tissues, it facilitates NV in the retina and subretinal 
space. 
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